SOTIO Biotech

SOTIO Biotech is at the forefront of shaping the future of cancer immunotherapies, dedicated to translating cutting-edge science into tangible patient benefits. With a robust clinical pipeline, SOTIO is developing a next-generation PD-1-inhibiting cytokine, a proprietary technology enhancing CAR T therapy efficacy, and a new generation of potent and stable antibody-drug conjugates (ADCs).

SOTIO Biotech operates globally with key locations including its primary address at Českomoravská 2532/19b, Prague 9, Czech Republic 190 00, CZ; Hochbergerstrasse 60c, Basel, Basel-Town 4057, CH; Strawinskylaan 933, Amsterdam, Netherlands 1077XX, NL; and 180 Canal Street, Suite 300, Boston, Massachusetts 02114, US. SOTIO's strategic presence ensures comprehensive research and development in critical regions.

As a member of the PPF Group, SOTIO Biotech continues to expand its innovative research and development efforts, strengthening its position as a leader in cancer immunotherapy. Further details about SOTIO Biotech's advancements and strategic direction will be completed soon with the support of the company’s management. We invite the manager of SOTIO Biotech to create a customized and exclusive company showcase and product listing on our platform.